Free Trial

Compass Therapeutics (CMPX) Competitors

Compass Therapeutics logo
$2.70 -0.15 (-5.26%)
Closing price 04:00 PM Eastern
Extended Trading
$2.73 +0.03 (+1.11%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CMPX vs. ETNB, ANIP, MESO, EWTX, JANX, TVTX, CVAC, CALT, GPCR, and AUPH

Should you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include 89BIO (ETNB), ANI Pharmaceuticals (ANIP), Mesoblast (MESO), Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), Travere Therapeutics (TVTX), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry.

Compass Therapeutics vs. Its Competitors

Compass Therapeutics (NASDAQ:CMPX) and 89BIO (NASDAQ:ETNB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

68.4% of Compass Therapeutics shares are owned by institutional investors. 29.8% of Compass Therapeutics shares are owned by company insiders. Comparatively, 2.6% of 89BIO shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Compass Therapeutics' return on equity of -42.47% beat 89BIO's return on equity.

Company Net Margins Return on Equity Return on Assets
Compass TherapeuticsN/A -42.47% -38.31%
89BIO N/A -81.44%-70.17%

Compass Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, 89BIO has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500.

Compass Therapeutics currently has a consensus target price of $12.67, indicating a potential upside of 369.14%. 89BIO has a consensus target price of $26.43, indicating a potential upside of 140.26%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Compass Therapeutics is more favorable than 89BIO.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Compass Therapeutics
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
3.10
89BIO
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
3.00

Compass Therapeutics has higher revenue and earnings than 89BIO. Compass Therapeutics is trading at a lower price-to-earnings ratio than 89BIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compass Therapeutics$850K439.24-$49.38M-$0.41-6.59
89BION/AN/A-$367.08M-$3.38-3.25

In the previous week, 89BIO had 2 more articles in the media than Compass Therapeutics. MarketBeat recorded 4 mentions for 89BIO and 2 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 1.77 beat 89BIO's score of 0.47 indicating that Compass Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Compass Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
89BIO
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Compass Therapeutics beats 89BIO on 12 of the 15 factors compared between the two stocks.

Get Compass Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMPX vs. The Competition

MetricCompass TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$394.11M$2.99B$5.61B$9.11B
Dividend YieldN/A2.39%5.24%4.01%
P/E Ratio-6.5920.5827.9620.25
Price / Sales439.24292.00430.8999.65
Price / CashN/A42.8637.4658.16
Price / Book2.977.638.045.49
Net Income-$49.38M-$55.05M$3.18B$250.27M
7 Day Performance-2.70%8.54%3.72%4.78%
1 Month Performance11.11%5.38%3.72%7.20%
1 Year Performance159.62%2.35%29.92%17.27%

Compass Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMPX
Compass Therapeutics
3.0322 of 5 stars
$2.70
-5.3%
$12.67
+369.1%
+199.3%$394.11M$850K-6.5920News Coverage
Positive News
ETNB
89BIO
1.8989 of 5 stars
$9.82
-0.4%
$26.43
+169.1%
+24.6%$1.43BN/A-2.9140
ANIP
ANI Pharmaceuticals
3.6785 of 5 stars
$65.25
-0.4%
$80.13
+22.8%
+6.0%$1.41B$614.38M-51.38600News Coverage
Analyst Forecast
MESO
Mesoblast
2.335 of 5 stars
$10.89
-0.3%
$18.00
+65.3%
+48.3%$1.39B$5.67M0.0080Positive News
EWTX
Edgewise Therapeutics
1.576 of 5 stars
$13.11
-0.5%
$40.00
+205.1%
-35.5%$1.38BN/A-8.4660
JANX
Janux Therapeutics
1.9556 of 5 stars
$23.10
-0.2%
$95.25
+312.3%
-38.4%$1.37B$10.59M-16.9930News Coverage
Analyst Forecast
TVTX
Travere Therapeutics
3.6322 of 5 stars
$14.80
+0.2%
$32.14
+117.2%
+73.7%$1.31B$233.18M-5.27460
CVAC
CureVac
4.6868 of 5 stars
$5.43
+0.9%
$6.83
+25.8%
+75.2%$1.22B$579.18M5.90880Positive News
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180
GPCR
Structure Therapeutics
2.6129 of 5 stars
$20.74
-1.6%
$76.17
+267.2%
-54.8%$1.19BN/A-23.84136
AUPH
Aurinia Pharmaceuticals
3.0457 of 5 stars
$8.47
-2.0%
$11.50
+35.8%
+62.4%$1.14B$235.13M30.25300Positive News

Related Companies and Tools


This page (NASDAQ:CMPX) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners